Evidence map›Paper›PMID 27500926›Full record

ArticlePloS one2016

Efficacy of Tumor-Targeting Salmonella A1-R on a Melanoma Patient-Derived Orthotopic Xenograft (PDOX) Nude-Mouse Model.

Mako Yamamoto, Ming Zhao, Yukihiko Hiroshima, Yong Zhang, Elizabeth Shurell, Fritz C Eilber, Michael Bouvet, Makoto Noda, Robert M Hoffman

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
28.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 102 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Acta biochimica et biophysica Sinica · 2023
    Review
  6. Recombinant AttenuatedCancers · 2022
    Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Tumor-targetingHeliyon · 2018
    Article
  15. Article
  16. On the role of classical and novel forms of vitamin D in melanoma progression and management.The Journal of steroid biochemistry and molecular biology · 2018
    Review
  17. Article
  18. Article
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Mako YamamotoAntiCancer, Inc., Ostrow Street, San Diego, California, United States of America.
Ming ZhaoAntiCancer, Inc., Ostrow Street, San Diego, California, United States of America.
Yukihiko HiroshimaAntiCancer, Inc., Ostrow Street, San Diego, California, United States of America.
Yong ZhangAntiCancer, Inc., Ostrow Street, San Diego, California, United States of America.
Elizabeth ShurellDivision of Surgical Oncology, University of California Los Angeles, Los Angeles, California, United States of America.
Fritz C EilberDivision of Surgical Oncology, University of California Los Angeles, Los Angeles, California, United States of America.
Michael BouvetDepartment of Surgery, University of California San Diego, West Arbor Drive, San Diego, California, United States of America.
Makoto NodaDepartment of Molecular Oncology, Kyoto University Graduate School of Medicine, Yoshida-Konoe-cho, Sakyo-ku, Kyoto, Japan.
Robert M HoffmanAntiCancer, Inc., Ostrow Street, San Diego, California, United States of America.
AntiCancer (United States) · USUniversity of California, San Diego · USUniversity of California, Los Angeles · USKyoto University · JP

Funding

Pancreatic-Cancer Imageable Patient-Derived Orthotopic Xenografts (iPDOX)R43CA183280 · NCI · ANTICANCER, INC. · PI YANG, MENG · 2014 to 2014
$225k
NCI NIH HHS R43 CA183280
6 · The paper itself

Abstract

Tumor-targeting Salmonella enterica serovar Typhimurium A1-R (Salmonella A1-R) had strong efficacy on a melanoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. GFP-expressing Salmonella A1-R highly and selectively colonized the PDOX melanoma and significantly suppressed tumor growth (p = 0.021). The combination of Salmonella A1-R and cisplatinum (CDDP), both at low-dose, also significantly suppressed the growth of the melanoma PDOX (P = 0.001). Salmonella A1-R has future clinical potential for combination chemotherapy with CDDP of melanoma, a highly-recalcitrant cancer.

Indexed as

Disease Models, AnimalAnimalsAntineoplastic AgentsCombined Modality TherapyHumansMelanomaMiceMice, NudeSalmonella InfectionsSalmonella typhimuriumXenograft Model Antitumor AssaysAntineoplastic Agents

Identifiers

PMID27500926
PMCPMC4976963
OpenAlexW2516251801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.